ABD - İngilizce - NLM (National Library of Medicine)

merck sharp & dohme corp. - caspofungin acetate (unii: vuw370o5qe) (caspofungin - unii:f0xdi6zl63) - caspofungin 1 kg in 1 kg

Kanada - İngilizce - Health Canada

juno pharmaceuticals corp. - caspofungin (caspofungin acetate) - powder for solution - 50mg - caspofungin (caspofungin acetate) 50mg - echinocandins

Kanada - İngilizce - Health Canada

juno pharmaceuticals corp. - caspofungin (caspofungin acetate) - powder for solution - 70mg - caspofungin (caspofungin acetate) 70mg - echinocandins

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

accord healthcare s.l.u. - caspofungin acetate - candidiasis; aspergillosis - antimycotics for systemic use - treatment of invasive candidiasis in adult or paediatric patients.treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and/or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - caspofungin acetate, quantity: 55.5 mg - injection, powder for - excipient ingredients: mannitol; sucrose; carbon dioxide; sodium hydroxide; dilute hydrochloric acid - canspofungin is indicated for: ? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics ? treatment of: - invasive candidiasis, including candidaemia - oesophageal candidiasis - invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - caspofungin acetate, quantity: 77.7 mg - injection, powder for - excipient ingredients: sucrose; mannitol; carbon dioxide; sodium hydroxide; dilute hydrochloric acid - canspofungin is indicated for: ? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics ? treatment of: - invasive candidiasis, including candidaemia - oesophageal candidiasis - invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - caspofungin acetate -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - caspofungin acetate -

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - caspofungin acetate - powder for concentrate for solution for infusion - 50 milligram(s) - caspofungin

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - caspofungin acetate - powder for concentrate for solution for infusion - 70 milligram(s) - caspofungin